BV-R2 combination shows survival benefit across high-risk subgroups.
Ami Ali, PharmD, BCOP
Advertisement
Articles by Ami Ali, PharmD, BCOP
The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Pharmacists will play a significant role in TKI adherence rates among patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: AstraZeneca, White House Announce Most-Favored-Nation Deal
2
New Report Details Rising Incidence of Invasive Lobular Carcinoma
3
Tramadol and Antidepressants Linked to Increased Seizure Risk in Older Adults
4
FDA Approves Expanded Indication for Risperidone Extended-Release Injectable to Treat Bipolar I Disorder
5
